Document is current

Article History

Received: 6 August 2025

Accepted: 28 August 2025

First Online: 22 September 2025

Declarations

:

: Bernardino Alcázar-Navarrete declares conflicts of interest for having received consulting fees, research grants, or lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Grifols, GSK, Laboratorios Bial, Laboratorios Menarini, and Sanofi. Juan Marco Figueira-Gonçalves has received honoraria for speaking engagements and funding for conference attendance from AstraZeneca, Laboratories Esteve, MundiPharma, Boehringer Ingelheim, Ferrer, Menarini, Rovi, GSK, Chiesi, Novartis, and Gebro Pharma. Carmen Corregidor-García, Eunice Fitas, and Joaquín Sánchez-Covisa are employees of AstraZeneca.

: The present study was approved by the Ethics Committee of Complejo Hospitalario Universitario de Canarias (Santa Cruz de Tenerife) in Spain during the meeting held on the 25th of May 2024. The study was in accordance with ethical principles that are consistent with the Declaration of Helsinki (1964 and its later amendments), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice, and the applicable legislation on non-interventional studies and/or observational studies. Given the retrospective and non-interventional nature of the study and according to the current local regulations, the Ethics Committee endorsed a waiver for written informed consent from patients.